###begin article-title 0
Evidence That Kidney Function but Not Type 2 Diabetes Determines Retinol-Binding Protein 4 Serum Levels
###end article-title 0
###begin p 1
###xml 36 59 36 59 <email xmlns:xlink="http://www.w3.org/1999/xlink">henze@rz.uni-potsdam.de</email>
Corresponding author: Andrea Henze, henze@rz.uni-potsdam.de
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
OBJECTIVE- It has been suggested that retinol-binding protein 4 (RBP4) links adiposity, insulin resistance, and type 2 diabetes. However, circulating RBP4 levels are also affected by kidney function. Therefore, the aim of this study was to test whether RBP4 serum levels are primarily associated with kidney function or type 2 diabetes.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 302 303 302 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 305 306 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 337 338 337 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 340 341 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 372 373 372 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 375 376 375 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 409 410 409 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 412 413 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
RESEARCH DESIGN AND METHODS- RBP4 serum concentration was determined by enzyme-linked immunosorbent assay in 126 nondiabetic and 104 type 2 diabetic subjects. The study population was divided according to estimated glomerular filtration rate (eGFR) into the following groups: eGFR >90 ml/min per 1.73 m2 (n = 53), 60-90 ml/min per 1.73 m2 (n = 90), 30-60 ml/min per 1.73 m2 (n = 38), and <30 ml/min per 1.73 m2 (n = 49). Each group was subdivided into nondiabetic and type 2 diabetic subjects.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 71 72 70 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 131 132 130 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 134 135 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 403 404 402 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 415 416 414 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 439 440 438 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 450 451 449 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
RESULTS- RBP4 serum concentration was elevated (2.65 vs. 2.01 mumol/l; P < 0.001) and eGFR was reduced (56 vs. 74 ml/min per 1.73 m2; P < 0.001) in type 2 diabetic vs. nondiabetic subjects, respectively. By stratifying for eGFR, no more differences in RBP4 serum concentration were detectable between type 2 diabetic and nondiabetic subjects. A linear regression analysis revealed an influence of eGFR (r = -0.477; P < 0.001) but not A1C (r = 0.093; P = 0.185) on RBP4 serum concentration.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
CONCLUSIONS- Existing human data showing elevated RBP4 levels in type 2 diabetic patients may be the result of moderate renal insufficiency rather than support for the suggestion that RBP4 links obesity to type 2 diabetes.
###end p 6
###begin p 7
Published ahead of print at  on 16 September 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 176 177 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 413 414 389 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 531 532 507 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 533 534 509 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 633 634 609 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 635 636 611 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 637 638 613 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 713 714 689 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 715 717 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 853 854 829 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 855 856 831 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
Retinol-binding protein 4 (RBP4) is a small visceral protein (approximately21 kDa), mainly synthesized in the liver and catabolized in the kidneys after glomerular filtration (1). To prevent the renal loss of RBP4 before delivering its ligand retinol to the target tissues, RBP4 is complexed by transthyretin, a homotetrameric protein with a molecular weight of approximately55 kDa, formerly known as prealbumin (2). RBP4 was recently discussed as a new adipokine that is possibly linked to insulin resistance and type 2 diabetes (3-5). Although it is known that RBP4 serum levels are elevated in states of impaired kidney function (1,6-8) (which is a common feature of diabetes, metabolic syndrome, and obesity [9,10]), parameters of kidney function have not been reported in most of the studies concerning RBP4 and insulin resistance and/or diabetes (3-5). Therefore, the aim of this study was to determine whether RBP4 serum concentration is associated with kidney function rather than type 2 diabetes.
###end p 9
###begin title 10
RESEARCH DESIGN AND METHODS
###end title 10
###begin p 11
###xml 1009 1011 1003 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 1218 1219 1212 1213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 402 407 <span type="species:ncbi:9606">Human</span>
Serum samples of 230 age-matched subjects (131 male, including 59 with type 2 diabetes, and 99 female, including 45 with type 2 diabetes) were collected by the Department of Endocrinology, Diabetes and Nutrition and the Department of Nephrology-both of Charite-Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany-and by the Department of Clinical Nutrition of the German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany. The study protocol was approved by the ethics committees of the hospitals and the University of Potsdam. Written informed consent was obtained from each subject. Blood was taken from antecubital veins after an overnight fast and centrifuged, and serum was immediately frozen at -80degreesC until processing. The renal function of all subjects was quantified by the estimated glomerular filtration rate (eGFR), which was calculated using the simplified Modification of Diet in Renal Disease (MDRD) formula including serum creatinine concentration, age, and sex (11). The study population was subdivided into nondiabetic and diabetic subjects, and each subpopulation was assigned according to eGFR to the following groups: eGFR >90, 60-90, 30-60, and <30 ml/min per 1.73 m2.
###end p 11
###begin title 12
Measurement of laboratory parameters.
###end title 12
###begin p 13
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
Anthropometry was performed by the attending physician as previously described (12). Serum samples were analyzed for glucose, total cholesterol, LDL and HDL cholesterol, triglycerides, and creatinine with a Cobas Mira Analyzer (Roche, Mannheim, Germany). The intra-assay coefficients of variation (CVs) were as follows: glucose, 5.5%; total cholesterol, 5.1%; HDL cholesterol, 5.4%; and triglycerides, 5.1%. The amount of A1C was determined by an enzyme-linked immunosorbant assay as described elsewhere, with an intra-assay CV of 2.5% (12).
###end p 13
###begin title 14
Determination of RBP4 and transthyretin serum concentration.
###end title 14
###begin p 15
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 220 225 <span type="species:ncbi:9606">human</span>
The RBP4 and transthyretin serum levels were determined by a noncommercial enzyme-linked immunosorbant assay as previously described (8,13). For calibration of both assays, RBP4 and transthyretin standards obtained from human blood were used, respectively (N Protein Standard SL; Dade Behring, Marburg, Germany), representing the physiological (nontruncated) RBP4 and transthyretin forms.
###end p 15
###begin title 16
Statistical analysis.
###end title 16
###begin p 17
###xml 196 197 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 253 254 253 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Statistical analysis was accomplished using SPSS (version 15.0; SPSS, Chicago). Results are expressed as medians and ranges. The data were compared using the nonparametric procedures Mann-Whitney U test and Kruskal-Wallis test as appropriate. Values of P < 0.05 were considered significant.
###end p 17
###begin title 18
RESULTS
###end title 18
###begin p 19
###xml 96 103 96 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 139 140 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 237 238 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 315 316 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 327 333 325 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 417 418 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 419 420 417 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 552 553 550 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 617 618 615 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 653 654 651 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 665 671 663 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 741 742 739 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 743 744 741 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 1094 1095 1092 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1121 1127 1119 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 1365 1371 1363 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 1514 1515 1512 1513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1606 1607 1604 1605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1777 1778 1775 1776 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1859 1860 1857 1858 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1862 1863 1860 1861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2015 2016 2013 2014 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2016 2017 2014 2015 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s</sub>
###xml 2028 2029 2026 2027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2185 2192 2183 2190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 2254 2255 2249 2250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2317 2318 2309 2310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2610 2611 2602 2603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2624 2625 2616 2617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Anthropometric and clinical data were recorded by the attending physicians and are presented in Table 1. The whole type 2 diabetes cohort (n = 104) had elevated RBP4 serum levels in comparison with those of the whole nondiabetes cohort (n = 126) (median 2.65 mumol/l [range 0.68-8.03] vs. 2.01 mumol/l [0.59-7.97]; P = 0.001) (Fig. 1), confirming former results that RBP4 serum levels are related to type 2 diabetes (3-5). However, the diabetic subjects also revealed a reduction in kidney function, as indicated by a lower eGFR (56.0 ml/min per 1.73 m2 [4-117] for type 2 diabetic subjects vs. 74.1 ml/min per 1.73 m2 [3-126] for nondiabetic subjects; P < 0.001) (Fig. 1). Since the kidneys have a substantial influence on RBP4 metabolism (1,8), we tested whether the difference in RBP4 serum concentration between diabetic and nondiabetic subjects is consistent after stratifying for kidney function. To do so, we evaluated the RBP4 serum concentration of type 2 diabetic and nondiabetic subjects for all four groups individually; we were unable to detect any differences between the groups (P > 0.410 for all groups) (Fig. 2). Moreover, although there are no differences in RBP4 serum levels between type 2 diabetic and nondiabetic subjects with comparable eGFR, a gradual elevation of the RBP4 serum concentration was evident with progression of kidney injury (Fig. 2), resulting in the highest RBP4 levels for both type 2 diabetic and nondiabetic subjects measured in the group with eGFR <30 ml/min per 1.73 m2 in comparison with those of type 2 diabetic and nondiabetic subjects in all other groups (P < 0.01 for all groups). For the type 2 diabetic subjects, the difference in RBP4 serum concentration was also significant for the group with eGFR 30-60 ml/min per 1.73 m2 in comparison with those of the groups with eGFR >90 and 60-90 ml/min per 1.73 m2 (P < 0.01 for both). Furthermore, a significant inverse correlation between RBP4 serum concentration and eGFR was found (Spearman correlation coefficient rs = -0.452; P < 0.001). Finally, linear regression analysis with RBP4 as the dependent variable and including BMI, systolic and diastolic blood pressure, eGFR, and A1C (Table 2) revealed that eGFR (standardized beta-coefficient = -0.482; P < 0.001) but not A1C (standardized beta-coefficient = 0.093; P = 0.185) influcences RBP4 serum levels. This model was recalculated using either the presence of type 2 diabetes or fasting blood glucose instead of A1C; comparable with A1C, both parameters (presence of type 2 diabetes and fasting blood glucose) were not associated with RBP4 serum levels (P = 0.551 and P = 0.687, respectively).
###end p 19
###begin title 20
DISCUSSION
###end title 20
###begin p 21
###xml 122 123 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 226 227 226 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
Several studies demonstrated elevated RBP4 serum levels in subjects with obesity, insulin resistance, or type 2 diabetes (3-5,14,15). Although it is known that kidney dysfunction results in elevated RBP4 serum concentrations (1,6-8,16) and that not only diabetes but also the metabolic syndrome and obesity are related to kidney dysfunction (9,10,17-19), information about the kidney function (such as serum creatinine concentration, glomerular filtration rate, and proteinuria) are lacking in most of the studies concerning RBP4 in the complex pathogenesis of insulin resistance and type 2 diabetes. Therefore, the aim of this study was to assess the influence of kidney function on the RBP4 serum concentration in type 2 diabetic and nondiabetic subjects.
###end p 21
###begin p 22
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
By comparing the RBP4 serum concentration of type 2 diabetic and nondiabetic subjects irrespective of kidney function, we were able to confirm former findings and detected elevated RBP4 serum levels in type 2 diabetic subjects (3,4). However, type 2 diabetic subjects also revealed a diminished eGFR, indicating a reduced kidney function. Therefore, we stratified all subjects according to eGFR to evaluate the influence of kidney function on RBP4 serum levels. After stratification, no further differences in the RBP4 serum concentration were detectable between diabetic and nondiabetic subjects for each eGFR group. However, a decline in eGFR was accompanied by a gradual elevation of RBP4 serum levels in both type 2 diabetic and nondiabetic subjects, which was confirmed by the results of linear regression analysis, indicating an influence of eGFR but not of the presence of type 2 diabetes or other parameters of diabetes (A1C, fasting serum glucose, and BMI) on RBP4 serum concentration.
###end p 22
###begin p 23
###xml 358 359 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 360 361 360 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 362 363 362 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 414 415 414 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
These data indicate that elevation of RBP4 serum concentration is more likely to be caused by the presence of impaired kidney function rather than type 2 diabetes. Thus, previously described associations of type 2 diabetes, the metabolic syndrome, or obesity with elevated serum RBP4 levels might be explained by the concurrence of impaired kidney function (1,6-8), which is more commonly found in these subjects (9,10). Consequently, we suggest that future studies investigating the potential role of RBP4 in the pathogenesis of insulin resistance and/or type 2 diabetes consider kidney function as a potential confounder when interpreting the results. However, it remains to be elucidated whether the increased levels of RBP4 in states of impaired kidney function contribute to the manifestation of insulin resistance and type 2 diabetes.
###end p 23
###begin p 24
J.S. was supported by a Heisenberg Professorship by the Deutsche Forschungsgemeinschaft (SP 716/2[hypen]1) and a Nachwuchsgruppe "Molekulare Ernahrung" of the German Ministery of Education and Research (FKZ0315083).
###end p 24
###begin p 25
###xml 13 25 <span type="species:ncbi:9606">participants</span>
We thank all participants of the study and Elisabeth Pilz for her skillfull technical assistance in determining RBP4 and transthyretin serum levels.
###end p 25
###begin title 26
REFERENCES
###end title 26
###begin p 27
###xml 26 27 26 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 39 40 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 88 89 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
RBP4 serum concentration (A) and eGFR (B) in type 2 diabetic (n = 104) and nondiabetic (n = 126) subjects.
###end p 27
###begin p 28
RBP4 serum concentration in type 2 diabetic and nondiabetic subjects dependent on eGFR.
###end p 28
###begin p 29
Anthropometric and clinical data of the study population
###end p 29
###begin p 30
Data are medians (range) unless otherwise indicated.
###end p 30
###begin p 31
###xml 29 30 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 122 123 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Significant difference, with P < 0.05, between type 2 diabetic and nondiabetic subjects with an eGFR >90 ml/min per 1.73 m2.
###end p 31
###begin p 32
###xml 29 30 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 124 125 124 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Significant difference, with P < 0.05, between type 2 diabetic and nondiabetic subjects with an eGFR 60-90 ml/min per 1.73 m2.
###end p 32
###begin p 33
###xml 29 30 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 124 125 124 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Significant difference, with P < 0.05, between type 2 diabetic and nondiabetic subjects with an eGFR 30-60 ml/min per 1.73 m2.
###end p 33
###begin p 34
###xml 29 30 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 122 123 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Significant difference, with P < 0.05, between type 2 diabetic and nondiabetic subjects with an eGFR <30 ml/min per 1.73 m2. DBP, diastolic blood pressure; FBG, fasting blood glucose; SBP, systolic blood pressure; TTR, transthyretin.
###end p 34
###begin p 35
Linear regression analysis using RBP4 as the dependent variable and including BMI, systolic and diastolic blood pressure, eGFR, and A1C as independent variables
###end p 35
###begin p 36
DBP, diastolic blood pressure; SBP, systolic blood pressure.
###end p 36

